Clinical experience of the use of the complex remedy Trylumin in the management of patients who have suffered from coronavirus disease COVID-19 and chronic fatigue syndrome on the background of secondary immunodeficiency

Authors

  • V.V. Vasylovskyy SI “Institute of Neurology, Psychiatry and Narcology NAMS of Ukraine”, Kharkiv, Ukraine
  • A.A. Kosinov SI “L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases NAMS of Ukraine”, Kyiv, Ukraine
  • M.V. Golubtsova SI “L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases NAMS of Ukraine”, Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2224-0713.18.1.2022.927

Keywords:

chronic fatigue syndrome, coronavirus infection ­COVID-19, post-COVID syndrome

Abstract

Background. It has been established that COVID-19 most often leads to indirect neurological damage: hypoxic brain injury and immune-mediated CNS damage. Coronavirus infection has proven mechanisms of harmful effects on the nervous system and immunity, provoking the development of post-COVID chronic fatigue syndrome (CFS). The study was aimed to investigate the effectiveness of the immunomodulatory agent Trylumin in the complex therapy of patients who suffered from coronavirus disease ­COVID-19 and chronic fatigue syndrome on the background of secondary immunodeficiency. Materials and methods. To evaluate the effectiveness of complex therapy for post-COVID chronic fatigue syndrome on the background of secondary immunodeficiency, the results of clinical and immunological tests were taken into account and the quality of life of patients was assessed. Results. In the dynamics of observation in the study group at the monitoring points on days 12 and 22, there were recorded a more pronounced regression of clinical symptoms, full normalization of immunograms, including immunoregulatory index, and better quality of life. The obtained results of post-COVID CFS on the background of secondary immunodeficiency suggest that the addition of the immunocorrective remedy Trylumin to the management scheme of this disease helps to implement a comprehensive rehabilitation program: reduces the intensity of clinical manifestations, normalize the immunological parameters and recovery. Conclusions. The addition of the complex agent Trylumin to the algorithm of management of patients with post-COVID chronic fatigue syndrome leads to the normalization of immunological parameters, more pronounced regression of clinical symptoms, restores the quality of life of patients. Trylumin may be recommended to supplement the management regimen of patients who have suffered from COVID-19 coronavirus disease and chronic fatigue syndrome with secondary immunodeficiency.

Downloads

Download data is not yet available.

References

Avellaneda Fernández A., Pérez Martín A., Izquierdo Martínez M., et al. Chronic fatigue syndrome: aetiology, diagnosis and treatment. BMC Psychiatry. 2009. 9 Suppl. 1 (Suppl. 1). S1. Published 2009 Oct 23. doi: 10.1186/1471-244X-9-S1-S1.

Castro-Marrero J., Sáez-Francàs N., Santillo D., Alegre J. Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome. Br. J. Pharmacol. 2017. 174(5). 345-369. doi: 10.1111/bph.13702.

Noor N., Urits I., Degueure A., Rando L., Kata V., Cornett E.M., et al. A Comprehensive Update of the Current Understan-ding of Chronic Fatigue Syndrome. Anesth. Pain Med. 2021 Jun 26. 11(3). e113629. doi: 10.5812/aapm.113629. PMID: 34540633; PMCID: PMC8438707.

Sharpe M., Chalder T., White P.D. Evidence-Based Care for People with Chronic Fatigue Syndrome and Myalgic Encephalomyelitis. J. Gen. Intern. Med. 2021 Nov 17. doi: 10.1007/s11606-021-07188-4. Epub ahead of print. PMID: 34791590.

Natelson B.H., Haghighi M.H., Ponzio N.M. Evidence for the presence of immune dysfunction in chronic fatigue syndrome. Clin. Diagn. Lab. Immunol. 2002. 9(4). 747-752. doi: 10.1128/cdli.9.4.747-752.2002.

Arnett S.V., Alleva L.M., Korossy-Horwood R., Clark I.A. Chronic fatigue syndrome — a neuroimmunological model. Med. Hypotheses. 2011 Jul. 77(1). 77-83. doi: 10.1016/j.mehy.2011.03.030. Epub 2011 Apr 6. PMID: 21474251.

Bansal R.A., Tadros S., Bansal A.S. The presence of overlapping quality of life symptoms in primary antibody deficiency (PAD) and chronic fatigue syndrome (CFS). Allergy Asthma Clin. Immunol. 2020. 16. 21. Published 2020 Mar 30. doi: 10.1186/s13223-020-0417-3.

Roberts D. Chronic fatigue syndrome and quality of life. Patient Relat. Outcome Meas. 2018. 9. 253-262. Published 2018 Aug 1. doi: 10.2147/PROM.S155642.

Mensah F.K.F., Bansal A.S., Ford B., Cambridge G. Chronic fatigue syndrome and the immune system: Where are we now? Neurophysiol. Clin. 2017 Apr;. 47(2). 131-138. doi: 10.1016/j.neucli.2017.02.002. Epub 2017 Apr 12. PMID: 28410877.

Wildwing T., Holt N. The neurological symptoms of ­COVID-19: a systematic overview of systematic reviews, comparison with other neurological conditions and implications for healthcare services. Ther. Adv. Chronic Dis. 2021. 12. 2040622320976979. Published 2021 Jan 28. doi: 10.1177/2040622320976979.

Iadecola C., Anrather J., Kamel H. Effects of COVID-19 on the Nervous System. Cell. 2020. 183(1). 16-27.e1. doi: 10.1016/j.cell.2020.08.028.

Tu H., Tu S., Gao S., Shao A., Sheng J. The epidemiological and clinical features of COVID-19 and lessons from this global infectious public health event. J. Infect. 2020.

Cosentino G., Todisco M., Hota N., Della Porta G., Morbini P., Tassorelli C., Pisani A. Neuropathological findings from ­COVID-19 patients with neurological symptoms argue against a direct brain invasion of SARS-CoV-2: A critical systematic review. Eur. J. Neurol. 2021 Nov. 28(11). 3856-3865. doi: 10.1111/ene.15045. Epub 2021 Aug 17. PMID: 34339563; PMCID: PMC8444743.

Mackay A. A Paradigm for Post-COVID-19 Fatigue Syndrome Analogous to ME/CFS. Front Neurol. 2021. 12. 701419. Published 2021 Aug 2. doi: 10.3389/fneur.2021.701419.

Dyudyun A.D. Innovative approaches to treatment of urogenital infections. Medical aspects of women’s health. 2019. 4–5 (125–126). 60-66 (in Ukrainian).

Oliveira J.S., Hayes A. Clinimetrics: The EuroQol-5 Dimension (EQ-5D). J. Physiother. 2020 Apr. 66(2). 133. doi: 10.1016/j.jphys.2020.02.012. Epub 2020 Apr 11. PMID: 32291225.

Fisk J.D., Ritvo P.G., Ross L., et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clinical Infectious Diseases. 1994. 1. 79-83.

Published

2022-03-31

How to Cite

Vasylovskyy, V., Kosinov, A., & Golubtsova, M. (2022). Clinical experience of the use of the complex remedy Trylumin in the management of patients who have suffered from coronavirus disease COVID-19 and chronic fatigue syndrome on the background of secondary immunodeficiency. INTERNATIONAL NEUROLOGICAL JOURNAL, 18(1), 35–42. https://doi.org/10.22141/2224-0713.18.1.2022.927

Issue

Section

Original Researches

Most read articles by the same author(s)